Clinical Trials Directory

Trials / Completed

CompletedNCT00696774

Switching to Duloxetine in Patients With Depression

Attributes of Response in Depressed Patients Switched to Treatment With Duloxetine (ARDENT Study)

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
242 (actual)
Sponsor
Eli Lilly and Company · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to help answer the following research question: Whether switching to duloxetine improves depressed mood when current treatment did not work well for patients with depression.

Conditions

Interventions

TypeNameDescription
DRUGDuloxetineStudy Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks. Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more.

Timeline

Start date
2008-06-01
Primary completion
2009-07-01
Completion
2009-07-01
First posted
2008-06-13
Last updated
2010-09-08
Results posted
2010-08-11

Locations

2 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT00696774. Inclusion in this directory is not an endorsement.

Switching to Duloxetine in Patients With Depression (NCT00696774) · Clinical Trials Directory